Q.

What is the primary purpose of the chyme reinfusion therapy registry?

A.

To use real world data to help identify trends across the clinical outcomes of all patients using chyme reinfusion therapy.

Q.

What are the key objectives of establishing a registry like this?

A.

Determine the efficacy and safety of chyme reinfusion therapy and advance knowledge in the use and efficacy of chyme reinfusion therapy.

Q.

Who can access the Registry?

A.

Pseudo-anonymised data can be accessed by The Insides Company to support the post market surveillance requirements for medical device manufacturers. Other requests for access to the pseudo-anonymised data from the chyme reinfusion therapy registry will be assessed on a case-by-case basis and will always require regulatory and ethical approval prior to access being granted.

Q.

What kind of data and information is collected and stored in the registry?

A.

The chyme reinfusion therapy registry is an observational registry; this means that the data that is recorded will be guided by the tests and treatment pathways chosen by the patients treating clinical team.

Q.

Are there any specific patient privacy and data security measures in place for this registry?

A.

Patient data is entered into the registry in a pseudo-anonymised format and uses industry standard Amazon Web Servers with high level encryption. These processes comply with all data privacy laws relevant to the country where the data originates.

Q.

What regulatory approvals or certifications does the registry have to ensure its credibility and integrity?

A.

No data is entered into the registry until the relevant regulatory and ethical bodies in target countries have provided approval.

Q.

How can healthcare professionals or institutions participate in the registry?

A.

Reach out to The Insides Company to discuss the options for registry participation within your country.

Q.

What potential benefits can healthcare providers and researchers derive from the data collected in this registry?

A.

Expanding knowledge around the use of chyme reinfusion therapy in intestinal failure patients.